Skip to main content
OpenTrials

Clinical trial condition

Advanced Malignant Solid Neoplasm

Explore clinical trials studying Advanced Malignant Solid Neoplasm. Study availability and eligibility vary by location and protocol.

133 public trials 26 recruiting studies
Refine in advanced search Browse all conditions

Advanced Malignant Solid Neoplasm trial results

Active, Not Recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, +6 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, +80 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

NCT03842228

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • Keck Medicine of USC Buena Park Buena Park, California, United States
  • Keck Medicine of USC Koreatown Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Texas at Austin Austin, Texas, United States
  • University of Texas Medical Branch Galveston, Texas, United States
  • UT MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Conditions
Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Active, Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 116 locations
View Trial Details
Active, Not Recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613

Conditions
Advanced Malignant Solid Neoplasm, Breast Diseases, Breast Neoplasms, +39 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
View all 16 locations
View Trial Details

Related conditions